Metastatic Colorectal Cancers Completed Phase 2 Trials for Cetuximab (DB00002)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

DBCOND0063579 (Metastatic Colorectal Cancers)Completed2 IdentifierTitlePurposeDrugs
NCT01640444Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)Treatment
NCT00614393Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)Treatment
NCT00803647A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the LiverTreatment
NCT01919879Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal CancerTreatment
NCT00254137Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.Treatment
NCT00286130Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal CancerTreatment
NCT00326495BAY 43-9006 Plus Cetuximab to Treat Colorectal CancerTreatment
NCT00660582FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS TumorTreatment
NCT00689624Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal CancerTreatment
NCT01225744Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted TherapyTreatment
NCT01281761Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)Treatment